ImmunoGen, Inc. Announces Webcast of Presentation at the Susquehanna Financial Group's SIGnificant Investment Options in Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 22, 2007--ImmunoGen, Inc. (Nasdaq: IMGN) today announced that its presentation at the Susquehanna Financial Group's first annual SIGnificant Investment Options in Healthcare Conference will be webcast live. The presentation is scheduled to begin at 4:30 p.m. ET on March 1, 2007, and will be given at the Omni Berkshire Place hotel in New York City. The presentation will provide an update on ImmunoGen.
The webcast can be accessed through the "Investor Relations" section of the ImmunoGen website, http://www.immunogen.com. Following the live webcast, a replay of the presentation will be available at the same location until March 8, 2007.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer biopharmaceuticals. The Company's proprietary Tumor-Activated Prodrug (TAP) technology uses tumor-targeting antibodies to deliver a potent cell-killing agent specifically to cancer cells. Two TAP compounds wholly owned by ImmunoGen are in clinical testing - huN901-DM1 and huC242-DM4. Companies licensing the right to develop anticancer compounds to specific targets using ImmunoGen's TAP technology include Biogen Idec, Biotest AG, Centocor (Johnson & Johnson), Genentech, and sanofi-aventis. Three anticancer compounds are in clinical testing through ImmunoGen's collaborations with other companies - AVE9633 and AVE1642, in development by sanofi-aventis, and trastuzumab-MCC-DM1, in development by Genentech.
CONTACT:
Investors
ImmunoGen, Inc.
Carol Hausner
617-995-2500
Executive Director, Investor Relations and Corporate Communications
info@immunogen.com
SOURCE:
ImmunoGen, Inc.
